Anticoagulation in Acute Coronary Syndrome-State of the Art
Michel Zeitouni1, Mathieu Kerneis2, Tarek Nafee3
1Sorbonne University, ACTION Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.
Insights
Early anticoagulation is crucial for acute coronary syndrome (ACS) patients, balancing clot reduction and bleeding risk. This review examines heparin, enoxaparin, bivalirudin, and fondaparinux strategies for optimal ACS management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Early intravenous anticoagulation is a cornerstone in managing acute coronary syndromes (ACS).
- Anticoagulants aim to reduce coronary thrombosis and improve outcomes during percutaneous coronary intervention (PCI).
- Balancing ischemic benefits against bleeding risks is a key challenge in ACS treatment.
Purpose of the Study:
- To systematically review evidence-based data on anticoagulants used in ACS.
- To present strategies for using unfractionated heparin, enoxaparin, bivalirudin, and fondaparinux.
- To discuss anticoagulant selection in the context of evolving treatment paradigms like radial access and potent P2Y12 inhibitors.
Main Methods:
- Systematic review of randomized controlled trials and meta-analyses.
- Analysis of anticoagulant efficacy and safety profiles.
- Evaluation of treatment strategies considering patient-specific ischemic and bleeding risks.
Main Results:
- Different anticoagulants (heparin, enoxaparin, bivalirudin, fondaparinux) have established roles in ACS.
- The choice of anticoagulant is influenced by procedural access (radial vs. femoral) and concomitant antiplatelet therapy.
- Optimizing the antithrombotic regimen requires careful consideration of the individual patient's risk profile.
Conclusions:
- Anticoagulant selection in ACS is becoming more tailored, balancing efficacy and safety.
- Emerging trends necessitate a nuanced approach to anticoagulation in contemporary ACS management.
- Further research may refine optimal anticoagulant strategies in specific ACS patient subgroups.
Abstract:
Early intravenous anticoagulation is the corner stone treatment of patients admitted with an acute coronary syndrome: it antagonizes the ongoing coronary thrombosis and facilitates the percutaneous coronary intervention, hence a reduction of mortality and acute stent thrombosis. Unfractionated heparin, enoxaparin, bivalirudin and fondaparinux have been extensively studied in large randomized control trials and meta-analyses with the same objective: reducing the ischemic burden without hiking hemorrhagic events. This conundrum is evolving along the generalization of the radial-artery access, the use of potent P2Y12 and the trend towards a tailored approach regarding the ischemic and bleeding balance. In this systematic review, we aimed at presenting the evidence based data and strategies for each anticoagulant in the setting of acute coronary syndrome with and without ST-segment elevation.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...